While accumulating evidence supports the cardioprotective effects of SGLT2 inhibitors across various heart failure phenotypes [135,136,137,138,139,140] and increasingly within aortic stenosis (AS), robust data from prospective, AS-specific randomized trials remain limited. This evidence concerns the gene SLC5A2 and aortic stenosis.